Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that Sanofi intends to expand the clinical development program for the auto-immune skin disease drug KT-474 following a preliminary review that showed robust early data. Sanofi’s plan to broaden Phase II trials for the drug, which is aimed at hidradenitis suppurativa (HS) and atopic dermatitis (AD), reflects an intention to expedite progression towards pivotal studies. This news led to a surge in Kymera’s share price, which increased by more than 23% by the close of trading yesterday.
Kymera is recognized as a pioneer in the targeted protein degradation (TPD) field. The company’s KT-474 (SAR444656) is a novel IRAK4 degrader that is being developed to treat immune-inflammatory diseases such as HS and AD.
The partnership between Sanofi and Kymera began in 2020, with the French pharmaceutical giant making an upfront payment of USD 150 million and committing to potential milestones of up to USD 2 billion for the development of IRAK4-targeted degraders. This collaboration is strategic for finding a successor to Sanofi’s current blockbuster AD treatment, Dupixent (dupilumab).- Flcube.com
